PA
TSHA icon

Profund Advisors’s Taysha Gene Therapies TSHA Stock Holding History

Profund Advisors’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$602K Buy
134,671
+6,081
+5% +$28.3K 0.02% 485
2025
Q4 		$707K Buy
128,590
+75,224
+141% +$365K 0.02% 447
2025
Q3 		$175K Buy
53,366
+26,767
+101% +$75.8K 0.01% 1004
2025
Q2 		$61.4K Buy
+26,599
New +$57.8K ﹤0.01% 984
2025
Q1 		– Sell
-50,242
Closed -$86.9K – 1111
2024
Q4 		$86.9K Buy
+50,242
New +$104K ﹤0.01% 1079

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Profund Advisors's TSHA Position: Q1 2026 in Review

Profund Advisors increased its Taysha Gene Therapies (TSHA) stake by 4.7% in Q1 2026, buying an estimated $28.3K and bringing the position to 134,671 shares worth $602K. The position accounts for 0.02% of the portfolio, ranked #485.

Profund Advisors first reported a position in TSHA in Q4 2024 and has held it in 5 quarters since. The position peaked at $707K in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Profund Advisors held 134,671 shares of Taysha Gene Therapies worth $602K as of Q1 2026.
  • Profund Advisors bought 6,081 Taysha Gene Therapies shares in Q1 2026, an estimated $28.3K.
  • Taysha Gene Therapies made up 0.02% of Profund Advisors's portfolio in Q1 2026, its #485 holding.
  • Profund Advisors first reported a position in Taysha Gene Therapies in Q4 2024 and has held it in 5 quarters since.
  • Profund Advisors's Taysha Gene Therapies position peaked at $707K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.